Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

10 evidence topics · 22 sources

Summary
  • PAP nonadherence, by definition: with adherence defined as more than 4 hours of nightly use, 46% to 83% of people with OSA have been reported to be nonadherent (Weaver and Grunstein 2008). Relative to a 7-hour night, the overall CPAP non-adherence rate across 20 years of studies was 34.1%, with no significant improvement over that period (Rotenberg et al. 2016). By the CMS definition (at least 4 hours of use on 70% of nights in a consecutive 30-day period within the first 90 days), the observed 90-day adherence rate was 75% (Cistulli et al. 2019), which also cites prior studies in which up to 24% of patients may not fulfill their PAP prescription. The VA/DoD 2025 guideline states that as many as half of patients prescribed PAP have been unable to adopt it long-term. Mean adherence in the CPAP groups of two cardiovascular outcome trials was 3.3 hours per night (McEvoy et al. 2016) and 2.78 hours per night (Sánchez-de-la-Torre et al. 2020).
  • PAP termination and persistence: in claims data, with termination defined as cessation of CPAP reimbursements, termination rates among 480,000 people were 23.1%, 37.1%, and 47.7% after 1, 2, and 3 years (Pépin et al. 2021); a second analysis of 174,270 individuals reported a 1-year termination rate of 22.3% (Bailly et al. 2024). Under telemonitoring (95.7% of 84,550 people), PAP persistence was 83.5% at 1 year, 68.4% at 3 years, and 60.5% at 5 years, and issues with PAP treatment accounted for 54.9% of documented reasons for stopping (Baillieul et al. 2026).
  • Cardiovascular outcomes: CPAP did not reduce cardiovascular events in randomized trials. In one trial (McEvoy et al. 2016), a primary end-point event occurred in 17.0% of the CPAP group and 15.4% of the usual-care group after a mean 3.7 years (hazard ratio 1.10; 95% CI 0.91 to 1.32). Cardiovascular events occurred in 16% vs 17% in a second trial (Sánchez-de-la-Torre et al. 2020; hazard ratio 0.89; 95% CI 0.68 to 1.17), and the primary endpoint in 18.1% vs 22.1% in a third (Peker et al. 2016; hazard ratio 0.80; 95% CI 0.46 to 1.41). A meta-analysis of 10 randomized trials (7266 participants) found a relative risk of 0.77 (95% CI 0.53 to 1.13) for a composite of acute coronary syndrome, stroke, or vascular death. An individual participant data meta-analysis (4186 participants) found a hazard ratio of 1.01 (95% CI 0.87 to 1.17) for the first major adverse cardiac or cerebrovascular event, and 0.69 (95% CI 0.52 to 0.92) with good adherence in an on-treatment analysis. The AASM guideline finds insufficient and inconclusive evidence to recommend or withhold PAP in non-sleepy adults to reduce cardiovascular events or mortality.
  • Oral appliances: in pooled trials (hypopnea scoring rule not stated), the mean AHI reduction was 6.24 events/h greater with CPAP than with oral appliances, and the odds of reaching the target AHI in moderate to severe OSA were greater with CPAP; no randomized trial has compared objective oral appliance adherence with CPAP (AASM and AADSM guideline). The ERS guideline suggests CPAP over mandibular advancement devices (conditional recommendation, very low quality of evidence) and regards the two as equal in mild to moderate OSA.
  • Positional therapy: guideline recommendations apply to positional OSA (VA/DoD, weak for) and to mild or moderate position-dependent OSA with a nonsupine AHI below 15 events/h (ERS). In a review of 8 studies (323 participants; hypopnea scoring rule not stated), CPAP reduced the AHI by 6.4 events per hour more than positional therapy (2 studies), all studies were of short duration, and long-term effects could not be assessed. The VA/DoD guideline states that positional therapy was not associated with improved functional outcomes or quality of life, with very low confidence in the evidence.
  • Hypoglossal nerve stimulation: the FDA device criteria summarized by the VA/DoD guideline include moderate to severe OSA with an AHI of 15 to 100 events per hour and failure of or intolerance to PAP. The ERS guideline suggests against its use as first-line treatment and suggests it as salvage treatment for patients with an AHI below 50 events/h and a BMI below 32 kg/m2; its trials included about 10% of screened patients. In one randomized trial cited by the VA/DoD guideline, 72.5% of 138 participants experienced a total of 164 procedure- or study-related adverse events. Apnimed cites invasiveness, cost, and BMI and airway collapse pattern exclusions, and states that approximately 100,000 patients had received the therapy as of March 2025.
  • Tirzepatide: its OSA indication is limited to moderate to severe OSA in adults with obesity, with a reduced-calorie diet and increased physical activity; its OSA trials enrolled adults with an AHI of at least 15 and a BMI of at least 30 kg/m2. The AASM fact sheet states that there is no head-to-head evidence comparing it with other OSA treatments.
  • Wake-promoting agents: the solriamfetol and armodafinil labels indicate them to improve wakefulness in OSA and state that neither treats the underlying airway obstruction.